Pathologically elevated EpCAM expression orchestrates a coordinated oncogenic program involving HtrA2 downregulation-mediated apoptosis resistance, PD-L1 upregulation, Treg recruitment, and CD8+ T cell functional impairment, collectively facilitating immune evasion in breast carcinoma [61]. This evidence concerns the gene HTRA2 and breast carcinoma.